Bayer AG (BYR.L,BAY.MI,BAYN.DE) and its independently operated subsidiary BlueRock Therapeutics LP announced that its investigational cell therapy, OpCT-001, has received Orphan Drug Designation from the FDA for treating retinitis pigmentosa. OpCT-001 is an investigational induced pluripotent stem cell-derived cell therapy being tested in a Phase 1/2a clinical study for the treatment of primary photoreceptor diseaseses.
Amit Rakhit, BlueRock's Chief Medical Officer, said: "We believe that OpCT-001 has great promise as a potential therapeutic option for restoring vision in people living with retinitis pigmentosa and other primary photoreceptor diseases and look forward to continuing to work with the FDA on its clinical development."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.